News · 26 weeks28+233%
2025-10-262026-04-19
Mix1990d
- Insider11(58%)
- SEC Filings4(21%)
- Other2(11%)
- Earnings2(11%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Mcgarrity Michael3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sollee Joseph3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bednarski Eric3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bellano John3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kalfus Ron3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hardison Don M3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Siegel Sanford Jay3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hoffman Koen3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Windels Hilde3 - MDxHealth SA (0001872529) (Issuer)
- SECSEC Form S-8 filed by MDxHealth SAS-8 - MDxHealth SA (0001872529) (Filer)
- INSIDERSEC Form 3 filed by new insider Holder Michael3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mvm Partners, Llc3 - MDxHealth SA (0001872529) (Issuer)
- PRMdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London. The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford,
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- PRMdxhealth Announces Fourth Quarter and Full-Year 2025 Financial ResultsMdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consiste
- SECSEC Form EFFECT filed by MDxHealth SAEFFECT - MDxHealth SA (0001872529) (Filer)
- PRMdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title:Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results andCorporate Update Conference Call and WebcastDate:February 26, 2026Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:Un
- SECAmendment: SEC Form F-3/A filed by MDxHealth SAF-3/A - MDxHealth SA (0001872529) (Filer)
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SASCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- PRMDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact SciencesMDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full year 2025 revenues of approximately $30.5 million and $109 million, respectively, representing year-over-year growth of 23% and 21%, respectively. During the fourth quarter, the Company billed 11,201 tissue-based units and 27,486 liquid-based
- PRMdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancerMdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, further validating th
- SECSEC Form F-3 filed by MDxHealth SAF-3 - MDxHealth SA (0001872529) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SASCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)